National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 11 of 2001)

Overview

The National Health Act 1953 was enacted to establish and maintain the Pharmaceutical Benefits Scheme (PBS), which ensures that essential medicines are affordable and accessible to Australians. This Act was introduced to address the need for a structured and regulated system to provide subsidised medications to the public, ensuring equitable access to necessary pharmaceutical products. The enactment of this Act was a pivotal step towards the establishment of a national health scheme by the Commonwealth Parliament, aiming to provide a consistent and comprehensive approach to public health medication subsidies. The policy objective behind the Act is to enable the provision of affordable medications, thereby improving public health outcomes and ensuring that the cost of medications does not impede access to essential treatments.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 applies to the specific drugs and medicinal preparations listed in the Schedule, which includes Bismuth Subcitrate, Cerivastatin Sodium, Ecothiopate Iodide, and others. These substances cease to be subject to Part VII of the Act, which governs the Pharmaceutical Benefits Scheme, from the commencement date of 1 November 2001. The Declaration is made by Brett Anthony Lennon, the Assistant Secretary of the Pharmaceutical Benefits Branch in the Department of Health and Aged Care, acting as a delegate for the Minister for Health and Aged Care. The scope of the Act is limited to these particular drugs, and it applies across the Commonwealth of Australia, thereby affecting entities and individuals involved in the distribution and supply of these pharmaceutical products. There are no stated exclusions, exemptions, or thresholds in the text, and the application of the Act is direct without extensions or restrictions through subordinate instruments.

Key Provisions

The primary operative sections of this Declaration (sections 2 and the Schedule) specify that certain drugs and medicinal preparations will no longer be covered under Part VII of the National Health Act 1953, which pertains to the Pharmaceutical Benefits Scheme (PBS). The Declaration, made by the Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Aged Care and Delegate of the Minister for Health and Aged Care, lists specific drugs and medicinal preparations that cease to be part of the PBS from 1 November 2001. These drugs include Bismuth Subcitrate, Cerivastatin Sodium, Ecothiopate Iodide, "Lofenalac", "Nutramigen", "O-Lac", Pilocarpine, "Portagen", "Pregestimil", and Thiabendazole. The cessation of these drugs and preparations from the PBS means they will no longer be subsidized under the scheme, impacting their availability and cost to consumers. The obligations imposed by this Act on the parties or entities it governs include ensuring that the listed drugs and preparations are no longer considered eligible for the PBS from the effective date of the Declaration. Health professionals, pharmaceutical suppliers, and patients must be made aware of this change, and relevant updates must be made to databases and information systems that track PBS-listed medications. The Department of Health and Aged Care, along with relevant stakeholders, must facilitate the transition smoothly to prevent disruptions in healthcare services. Failure to comply with the provisions of this Declaration could lead to civil and criminal consequences. Specifically, entities that continue to claim PBS benefits for the listed drugs after the effective date could be subject to fines and penalties. The exact penalties are not detailed in the Declaration itself but would be governed by the overarching provisions of the National Health Act 1953 and any related regulations or subsidiary legislation. These penalties could include substantial financial fines and potential legal action against individuals or entities found to be in breach of the Act’s provisions. Ensuring compliance with this Declaration is thus crucial for all stakeholders involved in the healthcare and pharmaceutical sectors.